These experiments were prompted by efforts to use cytokine-stimulation paradigms to increase IL13Rα2 expression on glioma cells and thereby increase the efficacy of IL13Rα2 targeted therapies for brain tumors [8]–[12]. This evidence concerns the gene IL13RA2 and brain neoplasm.